We are live on ! Find out more
DMK

DMK Pharmaceuticals Corporation Common Stock
DMK

Delisted

DMK was delisted on the 6th of February, 2024.

Back to rankings

52 hedge funds and large institutions have $14.6M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

255% more call options, than puts

Call options by funds: $2.53M | Put options by funds: $713K

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 51 → 52 (+1)

18% less capital invested

Capital invested by funds: $17.8M → $14.6M (-$3.17M)

Holders
52
Holders Change
+1
Holders Change %
+1.96%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
13
Reduced
9
Closed
5
Calls
$2.53M
Puts
$713K
Net Calls
+$1.82M
Net Calls Change
+$894K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$566K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$513K
3
VF
Virtu Financial
New York
+$214K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$204K
5
Citadel Advisors
Citadel Advisors
Florida
+$71.6K

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.78M
2
GC
Greenlight Capital
New York
-$740K
3
Goldman Sachs
Goldman Sachs
New York
-$266K
4
Squarepoint
Squarepoint
New York
-$106K
5
PCM
Prelude Capital Management
New York
-$72.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$25K -$17.5K -239 -39%
BRWA
27
B. Riley Wealth Advisors
Florida
$25K – – –
CS
28
Credit Suisse
Switzerland
$24K +$26K +355 New
GSIS
29
Global Strategic Investment Solutions
Arizona
$22K – – –
SCA
30
Stonebridge Capital Advisors
Minnesota
$21K -$23.1K -315 -50%
Victory Capital Management
31
Victory Capital Management
Texas
$21K -$1.17K -16 -5%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$19K +$20.9K +286 New
FCMT
33
Founders Capital Management (Texas)
Texas
$17K – – –
RJA
34
Raymond James & Associates
Florida
$16K +$4.83K +66 +40%
Squarepoint
35
Squarepoint
New York
$13K -$106K -1,442 -88%
Bank of America
36
Bank of America
North Carolina
$13K +$1.98K +27 +17%
ACA
37
Affinity Capital Advisors
California
$13K +$13.8K +188 New
OC
38
Oppenheimer & Co
New York
$12K – – –
MOS
39
MGO One Seven
Ohio
$11K – – –
Osaic Holdings
40
Osaic Holdings
Arizona
$11K +$2.63K +36 +27%
Jane Street
41
Jane Street
New York
$11K +$11.6K +159 New
WWM
42
Wolff Wiese Magana
California
$10K – – –
Barclays
43
Barclays
United Kingdom
$8K +$1.9K +26 +33%
FCM
44
Firestone Capital Management
Florida
$6K – – –
HCP
45
Hexagon Capital Partners
Arkansas
$5K – – –
TF
46
TimeScale Financial
Massachusetts
$5K – – –
AF
47
Allworth Financial
California
$3K – – –
HI
48
Harbour Investments
Wisconsin
$2K – – –
Wells Fargo
49
Wells Fargo
California
$1K -$73 -1 -7%
S
50
SignatureFD
Georgia
$1K – – –
1
2
3

DMK Hedge Fund Activity: Q3 2021 in Review

52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2021, worth a combined $14.6M — down 18% from $17.8M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DMK positions and 5 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, adding an estimated $566K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.78M sold.

  • 52 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2021, up from 51 in Q2 2021.
  • Funds reported $14.6M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2021, down 18% quarter-over-quarter.
  • 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2021 and 5 closed out, a net change of +1 holder.
  • The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2021 was Millennium Management, an estimated $566K added.
  • The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2021 was Balyasny Asset Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q3 2021.